As per the letter attached

10th August, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, G. Block, Bandra Kurla Dalal Street, Complex, Bandra (East), Mumbai 400 001 Mumbai - 400 051 Script Code: 500259 Script Code: LYKALABS Dear Sir/Madam, Sub: Outcome of the Board Meeting – 10th August, 2026 Ref: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the SEBI Listing Regulations) With reference to the above captioned subject and pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company in their meeting held today i.e. 10th August, 2026, has inter-alia, considered, approved and taken on record the following: 1. Unaudited Financial Results for the first quarter ended 30th June, 2026 Unaudited Financial Results (Standalone & Consolidated) for the first quarter ended 30th June, 2026 alongwith Limited Review Report thereon is enclosed herewith as Annexure -1. 2. Consider and approve disinvestment of shares from Lyka BDR International Limited With reference to the above and in compliance with Regulation 30 of SEBI LODR, we hereby inform you that the Board of Directors of the Company at its meeting held on 10th August, 2026, inter alia, has considered and approved the proposal for divestment of 100% Equity stake/investment held in its subsidiary company viz. Lyka BDR International Limited. Further, requisite authority has been delegated to Audit committee of the Company to take necessary steps in this regard. Lyka BDR International Limited is not a material subsidiary of the Company. The disclosure required under Regulation 30 of the SEBI LODR read with Disclosure Circular, are enclosed herewith as Annexure - 2. The above information will also be available on the website of the Company at www.lykalabs.com. The meeting of the Board of Directors commenced at 11.00 A.M. and concluded at 12.20 PM. Kindly take the same on your record. Thanking you, Yours faithfully, For Lyka Labs Limited Shailendra Agrawal Company Secretary and Compliance Officer Encl.: as above Ok D. KOTHARY & CO. Chartered Accountants INDIA Independent Auditor's Review Report on the Unaudited Standalone Financial Results for the quarter ended June 30, 2026 of the Company Pursuant to the Regulation 33 of the SEBI (l isting Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Lyka Labs Limited 1. We have reviewed the accompanying statement of unaudited standalone financial results of Lyka Labs Limited ("the Company") for the quarter ended June 30, 2026 ("the Statement’') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). 2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Tnd AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement. For D. Kothary be Co. Chartered Accountants Firm Rd^ismaticm No. 105335W Mehul .IfR’atel O (Partner) Membership No. 132650 UDIN: 2C5|32^50GtXlSlAl Place: Mumbai Date: August 10, 2026 102-Ameya House, Nextto Azad Nagar Metro Station, Above Standard Chartered Bank, Andheri (W), Mumbai - 400 058. Tel (B): +91 22 6865 1155/1166/ 1111 • E-mail: info@dkothary.com • Website : www.dkothary.com Lyka Labs Limited L-VJ^A Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 • Phone : 6611 2200/290 Website : www.lykalabs.com • Email: enquiry@lykalabs.com HealthcareThroughInnovation Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2026 in lakhs) Quarter Ended Year Ended 30th Jun, 2026 31st Mar, 2026 30th Jun, 2025 31st Mar, 2026 Particulars (Unaudited) (Unaudited) (Unaudited) (Audited) I Revenue Revenue from Operations 4230.94 2803.07 2917.64 12090.53 Other Income 41.85 50.98 77.34 397.44 Total Income 4272.79 2854.04 2994.98 12487.96 III Expenses (a)Cost of Materials Consumed 1120.41 742.58 804.94 3177.43 (b)Purchase of Stock in trade 750.15 499.88 224.86 1479.99 (c)Change in inventories of Finished Goods, (225.72) (139.66) 15.97 (107.94) work-in-progress and stock-in-trade (d)Employee benefits expense 1147.61 1287.29 898.24 4160.22 (e)Finance Costs 100.82 87.33 85.14 332.67 (f) Depreciation and amortisation expense 200.96 204.39 211.18 845.98 (g)Other expenses 979.21 861.23 637.91 3621.71 Total Expenses 4073.44 3543.04 2878.24 13510.05 IV Profit / (Loss) before Exceptional Items 199.35 (688.99) 116.74 (1022.09) and Taxes (II - III) V Exceptional Items (Net) 2301.44 2301.44 VI Profit / (Loss) before Tax 199.35 (2990.43) 116.74 (3323.53) VII Tax Expenses Current Tax (49.00) 31.00 Earlier YearTax 82.79 82.79 Deferred Tax (10.68) (47.01) 4.67 (177.48) VIII Net Profit / (Loss) after Tax 210.03 (2977.21) 81.07 (3228.84) IX Other Comprehensive Income (12.56) (14.40) (Net of Tax) - Net Credit / (Charge) X Total Comprehensive Income / (Loss) 210.03 (2989.77) 81.07 (3243.25) Paid up Equity Share Capital (FV ^ 10/- each) 3615.27 3615.27 3615.27 3615.27 Other Equity 5084.64 XI Basic and diluted earnings per share 0.58 (8.24) 0.22 (8.93) (Not annualised for the quarters) Regd. Office : 4801 / B & 4802 / A, G.I.D.C. Industrial Estate, Ankleshwar - 393 002. • Phone : 02646 221422 / 220549 • Fax : 02640-250692 CIN L24230GJ1976PLC008738 Lyka Labs Limited Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 • Phone : 6611 2200/290 Website : www.lykalabs.com • Email: enquiry@lykalabs.com Ilt'althcarrTlirou^liInnovation Notes: 1 The above Unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 10th August 2026. 2 The Hon'ble Nationa [Showing first 8,000 characters — download PDF for full document]